TICKERNERD
Menu
DVADVAHealthcare · Medical Care Facilities

DVA Stock Forecast: DaVita, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$174
−0.81% on the day

The 8 Wall Street analysts covering DaVita, Inc. hold a median 12-month price target of $220 — +26.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.1B
Ticker Nerd rank
90 / 100
Median analyst target
$220
Analysts covering
8
Total return, dividends reinvested
1W
−3.5%
1M
−26.7%
YTD
+53.0%
1Y
+26.3%
From 52W high
−27.9%
From 52W low
+67.3%
$104
$241
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DaVita, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
93
Quality
84
Volatility
81
Accruals
80
Growth
74
Momentum
70
Issuance
70
Revisions
57
Size
14

Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (57): Analysts have, on balance, been cutting their forecasts.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Oct 25Jan 26Apr 26Jul 26DVAHigh $270Median $220Low $165

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
3 Buy4 Hold1 Sell
Low $165Median $220High $270

The green dot is the last close — the median target sits +26.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
7 Aug 2026TD CowenUpgradeBuy$201 → $220
7 Aug 2026Truist SecuritiesMaintainsHold$250 → $215
5 Aug 2026BarclaysMaintainsEqual-Weight$218 → $224
14 July 2026Truist SecuritiesMaintainsHold$205 → $250
14 July 2026Truist SecuritiesMaintainsHold—
10 July 2026UBSMaintainsBuy$235 → $270
10 July 2026UBSMaintainsBuy—
9 July 2026BarclaysMaintainsEqual-Weight$194 → $218
9 July 2026BarclaysMaintainsEqual-Weight—
11 May 2026TD CowenMaintainsHold—
8 May 2026BarclaysMaintainsEqual-Weight—
8 May 2026Truist SecuritiesMaintainsHold—
7 May 2026UBSMaintainsBuy—
6 May 2026Deutsche BankUpgradeBuy—
4 Feb 2026UBSMaintainsBuy—
3 Feb 2026BarclaysMaintainsEqual-Weight—
3 Nov 2025TD CowenMaintainsHold—
30 Oct 2025BarclaysMaintainsEqual-Weight—
9 Oct 2025BarclaysMaintainsEqual-Weight—
10 Sept 2025B of A SecuritiesMaintainsUnderperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DVA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.0%
Analysts raising
3
Analysts cutting
3
Fundamentals

DaVita, Inc. (DVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.7×

Cheaper than 47% of US stocks

Price / sales
0.8×

Cheaper than 75% of US stocks

Price / book
10.4×

Cheaper than 10% of US stocks

EV / EBITDA
9.1×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
5.2%

Higher than 39% of US stocks

Earnings growth (YoY)
33.1%

Higher than 68% of US stocks

Gross margin
32.7%

Higher than 39% of US stocks

Operating margin
16.1%

Higher than 74% of US stocks

Net margin
6.0%

Higher than 62% of US stocks

Returns & dividend
Return on equity
88.5%

Higher than 96% of US stocks

Return on assets
7.5%

Higher than 87% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
DVADaVita, Inc.$11.1B
90
EHCEncompass Health Corp.$11.9B
81
UHSUniversal Health Services, Inc.$10.4B
66
ENSGThe Ensign Group, Inc.$10.4B
67
CHEChemed Corp.$7.3B
89
PACSPACS Group, Inc.$6.9B
93
THCTenet Healthcare Corp.$22.6B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DaVita, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DVA news & analysis

Is DaVita (DVA) a Great Value Stock Right Now?

Zacks Investment Research · 6 Aug 2026neutral

Zacks Investment Research examines whether DaVita (DVA) qualifies as a strong value stock, applying its Zacks Rank system, which centers on earnings estimates and estimate revisions, alongside current value, growth, and momentum trends.

Why it matters — A DVA watcher would care because the piece offers an analytical look at the stock's appeal based on earnings estimate revisions and value, growth, and momentum metrics.

DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down

Zacks Investment Research · 5 Aug 2026negative

DaVita's second-quarter 2026 results showed profit growth but were marked by narrowing margins and a weaker commercial mix, which weighed on performance. The stock declined in pre-market trading despite the earnings beat.

Why it matters — DVA watchers would care because margin compression and a weaker commercial mix offset the company's profit growth and earnings beat, pressuring the stock.

DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth

Zacks Investment Research · 5 Aug 2026neutral

DaVita's Q2 earnings call centered on clinical-led volume growth, driven by mortality-led volume gains and broader access to middle molecule clearance. Management maintained its 2026 guidance despite ongoing reimbursement pressure.

Why it matters — The call gives DaVita watchers insight into how clinical-led volume growth is offsetting reimbursement pressure and backing the company's maintained 2026 outlook.

DaVita Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

DaVita reported second-quarter results in line with expectations, citing accelerating treatment-volume growth and lower patient mortality, and reaffirmed its full-year 2026 guidance while outlining plans to expand access to newer dialysis technology.

Why it matters — A DVA watcher would care because the results indicate improving operational trends and the company's commitment to advancing its dialysis technology, which could support long-term growth.

DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of DaVita, Inc.'s (DVA) second-quarter 2026 earnings conference call. The transcript covers management's remarks from the Q2 2026 earnings call.

Why it matters — A DVA watcher would look to the Q2 2026 earnings call transcript for management's commentary on the company's quarterly performance and outlook.

FAQ

Frequently asked questions about DVA stock

What is the DVA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering DaVita, Inc. have a median 12-month price target of $220, with estimates ranging from $165 to $270. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DVA stock a buy right now?

Of the 8 analysts covering DaVita, Inc., 3 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks DaVita, Inc. 90 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DVA?

As at 22 Aug 2026, DaVita, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).

Will DVA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +26.6% from the last close, and Ticker Nerd's factor model ranks DaVita, Inc. 90 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DVA stock forecast for 2030?

No analyst covering DaVita, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $270 over the next 12 months.

How has DVA stock performed over the past year?

DaVita, Inc. returned +26.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DaVita, Inc. do?

DaVita Inc. is a healthcare services company specializing in kidney care, with a primary focus on providing dialysis treatments for patients with chronic kidney failure and end-stage renal disease.

What is the latest news on DVA?

The most recent item we track (Zacks Investment Research, 6 Aug 2026): "Is DaVita (DVA) a Great Value Stock Right Now?". Zacks Investment Research examines whether DaVita (DVA) qualifies as a strong value stock, applying its Zacks Rank system, which centers on earnings estimates and estimate revisions, alongside current value, growth, and momentum trends.

Company

About DaVita, Inc.

DaVita Inc. is a healthcare services company specializing in kidney care, with a primary focus on providing dialysis treatments for patients with chronic kidney failure and end-stage renal disease. The company operates a large network of outpatient dialysis centers, where it delivers in-center hemodialysis and related care services to adult patients across the United States and internationally. DaVita Inc. also supports home-based dialysis modalities, offering peritoneal dialysis and home hemodialysis, along with clinical education and support programs to help patients manage treatment outside the clinic setting. In addition, the company operates clinical laboratories that perform routine and specialized tests for dialysis patients and provides management and administrative services to affiliated outpatient centers. Headquartered in Denver, Colorado, DaVita Inc. plays a significant role in the healthcare system by serving a critical, medically complex patient population and working alongside physicians, hospitals, and payers to coordinate kidney care and related services.

CEO Mr. Javier J. Rodriguez · 78,000 employees · United States · https://www.davita.com